Review

Mesenchymal Stem or Stromal Cells from Amnion and Umbilical Cord Tissue and Their Potential for Clinical Applications

Andrea Lindenmair 1,2,*, Tim Hatlapatka 3,†, Gregor Kollwig 3, Simone Hennerbichler 2,4, Christian Gabriel 2,4, Susanne Wolbank 1,2, Heinz Redl 1,2 and Cornelia Kasper 3,*

1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna/Linz 1200, Austria; E-Mails: Andrea.Lindenmair@o.roteskreuz.at (A.L.); Susanne.Wolbank@TRAUMA.LBG.AC.AT (S.W.); Office@TRAUMA.LBG.AC.AT (H.R.)
2 Austrian Cluster for Tissue Regeneration, Austria;
   E-Mails: Simone.Hennerbichler@o.roteskreuz.at (S.H.); Christian.Gabriel@o.roteskreuz.at (C.G.)
3 Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna 1190, Austria; E-Mails: Tim.Hatlapatka@boku.ac.at (T.H.); Gregor.Kollwig@boku.ac.at (G.K.)
4 Red Cross Blood Transfusion Service of Upper Austria, Linz 4020, Austria

† These authors contributed equally to this work.
* Author to whom correspondence should be addressed; E-Mail: Cornelia.Kasper@boku.ac.at; Tel.: +43-1-47-654-6557; Fax: +43-1-47-654-6675.

Received: 4 September 2012; in revised form: 29 October 2012 / Accepted: 5 November 2012 / Published: 12 November 2012

Abstract: Mesenchymal stem or stromal cells (MSC) have proven to offer great promise for cell-based therapies and tissue engineering applications, as these cells are capable of extensive self-renewal and display a multilineage differentiation potential. Furthermore, MSC were shown to exhibit immunomodulatory properties and display supportive functions through parakrine effects. Besides bone marrow (BM), still today the most common source of MSC, these cells were found to be present in a variety of postnatal and extraembryonic tissues and organs as well as in a large variety of fetal tissues. Over the last decade, the human umbilical cord and human amnion have been found to be a rich and valuable source of MSC that is bio-equivalent to BM-MSC. Since these tissues are discarded after birth, the cells are easily accessible without ethical concerns.
1. Introduction

Mesenchymal cells derived from amniotic membrane have been referred to in various ways by different research groups, including human amnion/amniotic mesenchymal stromal cells (hAMSC[s]), amniotic membrane mesenchymal stem cells (AM-MSC), amniotic membrane-human mesenchymal stromal cells (AM-hMSC), amnion-derived MSC, amniotic mesenchymal fibroblasts, human amnion stromal cells (hASC), human amniotic mesenchymal tissue cells (AMTC), human amniotic mesenchymal cells (HAmc), mesenchymal cells derived from human amniotic membrane (MC-HAM), human amniotic mesenchymal stem cells (hAMS), human amniotic membrane-derived mesenchymal cells (hAMCs or hAM-MSC) and human amnion-derived fibroblast-like cells (HADFIIL) [1–25]. During the first meeting of the “International Placenta Stem Cell Society” (IPLASS) in 2007, it was agreed that the nomenclature of these cells should be unified as “human amniotic mesenchymal stromal cells” (hAMSC) [19].

hAMSC are derived from the extraembryonic mesoderm [19] and are found dispersed in the collagenous stroma underlying the epithelial monolayer of the amniotic membrane [2,16].

The nomenclature of umbilical cord (UC)-derived MSC has not been unified yet and the cells have been referred to in many ways, mainly depending on from which compartment of the cord the cells have been isolated. The UC usually comprises two arteries and a vein, which are immersed within a mucoid connective tissue, the so-called Wharton’s jelly (WJ), and are enclosed by a simple amniotic epithelium. At least four separate regions were found to contain mesenchymal cells. Thus, MSC could be isolated from the subendothelium [26–28], the WJ [29–39], the perivascular region [40,41], and the umbilical cord blood [42–46]. Parts of this review will focus on UC tissue-derived MSC which will be referred to as UC-MSC.

2. Isolation, Expansion and Characterization of hAMSC

Amniotic membrane is mechanically peeled off the chorionic membrane by blunt dissection, washed several times in a buffered solution and cut into small pieces. In most cases, hAMSC are obtained in subsequent enzymatic digestions. After complete removal of human amniotic epithelial cells (hAEC) by trypsin digestion, hAMSC are digested with various types and concentrations of collagenase (0.75–2 mg/mL) with or without adding DNase (20–75 μg/mL) [8,11,17,19,23,47–52]. Lisi et al. [14] have additionally added trypsin; Tawagawa et al. [53] have supplemented dispase and papain. Some groups have published that pure fractions of hAMSC can be obtained without previous isolation of hAEC treatment [10,49,52,54,55]. Due to the varying concentrations of collagenase used by the different groups, also the applied incubation times vary between 30 min and up to 3 h. For gaining both hAMSC and hAEC also reversed isolation protocols (hAEC after hAMSC) are published [52,56].
According to Parolini et al. [19], one single amnion should theoretically contain $5 \times 10^8$ hAMSC. Typically, one gram tissue yields in about $1 - 2 \times 10^6$ hAMSC [2,19]. Media used for expansion are usually composed of a basal medium, supplemented with fetal calf serum, antibiotics and antimycotics. The detailed compositions and some further used supplements that have been published for hAMSC expansion are listed in Table 1.

**Table 1.** Media used for expansion of human amnion/amniotic mesenchymal stromal cells (hAMSC); Abbreviations: FCS fetal calf serum, DMEM Dulbecco’s modified Eagles’s medium, EGF epidermal growth factor, M199 medium 199, b-ME beta-mercaptoethanol, NEAA nonessential amino acid, LIF leukemia inhibitory factor, MEM minimal essential medium eagle.

| Media | basal | % FCS |
|-------|-------|-------|
| Bilic [47,57] | DMEM:Ham'sF12 1:1 | 10 |
| | 50 ng/mL EGF, 2.5 μg/mL insulin, 5 μg/mL transferrin, 0.1 ng/mL tri-iodothyronine |
| Bilic [2] | DMEM:Ham'sF12 1:1 | 10 |
| | for some experiments 10 ng/mL EGF |
| Diaz-Prado [4] | DMEM | 20 |
| | 20 μg/mL EGF, 8 U/mL heparin |
| In't Anker [8] | M199 | 10 |
| | 3.7 mg/mL sodium bicarbonate |
| Kang [10] | alphaMEM | 10 |
| | 1% sodium pyruvate, 1% NEAA, 55 μM b-ME, 10 ng/mL EGF |
| König [12] | DMEM | 15 |
| | 1% NEAA, 55 μM 2-mercaptoethanol, 1 mM sodium pyruvate |
| Lisi [14] | DMEM | 10 |
| | without any further supplements or 10 ng/mL EGF |
| | or 10 ng/mL EGF + $10^3$ U/mL LIF |
| Paracchini [18] | DMEM | 10 |
| | 10 ng/mL EGF, 10 ng/mL LIF |
| Stadler [21] | DMEM | 10 |
| | 10 ng/mL EGF + $10^3$ U/mL LIF |
| Sudo [56] | alphaMEM | 10 |
| | 10 ng/mL EGF, 10 ng/mL LIF |
| Tamagawa [53] | alphaMEM | 10 |
| | 10 ng/mL EGF |
| Whittle [54] | DMEM | 10 |
| Zhao [25] | DMEM | 10 |

Some groups cultivate the cells in endothelial growth medium-2 (EGM-2) [12,13,21,55], which is a 2% serum medium supplemented with hydrocortisone, heparin, ascorbic acid, gentamicin sulfate and various growth factors (insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and fibroblast growth factor (FGF)).

One characteristic property of mesenchymal stem cells such as hAMSC is their plastic adherence. However, some groups published coating of the culture dishes with gelatin or fibronectin [8,12]. To remove non-adherent cells, medium is removed after a time of two h [18] up to seven days [1,8,14] after cell seeding. After reaching confluence of 70%–100%, cells are usually detached with trypsin (0.05% or 0.25%) with or without EDTA (0.02%) [1,4,8,11,14,18,21,53,56]. Alternatively, also
application of accutase is reported [12]. There is a great variability regarding seeding density, reaching from $1 \times 10^3$ c/cm$^2$ [1] up to $1.27 \times 10^5$ c/cm$^2$ [56].

Expansion of hAMSC is possible for at least five passages without any morphological alterations [1,2,9,14,19]. Some groups have even kept the cells in culture for 15 to 20 passages before reaching senescence [53,57].

hAMSC show fibroblast-like cell morphology, being spindle-shaped [4,11,19,53]. Regarding the ability to form colonies, there are differing reports. Soncini et al. [52] and Kim et al. [11], have shown clonal colony formation, whereas Bilic et al. [2] did not detect any clonal outgrowth, supposedly due to the lack of telomerase reverse transcriptase (TERT).

Analyzing the surface antigen profile by flow cytometry, polymerase chain reaction or immunocytochemistry staining, hAMSC are found to express the mesenchymal markers CD73, CD90 as well as CD105 and are further positive for CD10, CD13, CD29, CD44, CD49c, CD49d, CD49e, CD54, CD140b, CD166, CD349, STRO-1 and HLA-ABC [1,2,6,8,12,14,19,20,50,55,58]. Weak expression has been reported for CD271 [19,20] and CD117 (ckit) [2,4], in one case only being detected using PCR [58]. The hematopoietic markers CD34 and CD45, the monocyte marker CD14, the endothelial markers CD31 and CD133, as well as CD3 and CD11 are not expressed on hAMSC [1,2,5,6,8,12,14,19,50]. HLA-DR is reported to be absent or expressed at very low levels [1,2,6,8,12,14,49,55]. Paracchini et al. [18] analyzed low levels of EpCAM and CD49f in fresh hAMSC cultures, but these markers were rapidly decreasing during expansion. Immunofluorescence staining of amniotic membrane did not reveal SSEA-3 and SSEA-4 [59], however, surface expression of these markers on hAMSC is reported by several groups [4,6,11,18,19,58–60]. Furthermore, RNA levels of the transcription factor Oct-4 are reported [2,6,55,58] to be even higher than in bone marrow derived mesenchymal stem cells [1]. Transmission electron microscopy of hAMSC has revealed ultrastructural characteristics of mesenchymal as well as epithelial cells, showing a sign of multipotentiality [61].

3. Isolation, Expansion and Characterization of UC-MSC

Besides the umbilical cord blood the umbilical cord tissue was also found to be a rich and valuable source of MSC. For the isolation of the cells many protocols have been proposed mainly depending on from which compartment the cells should be isolated. An overview of different techniques applied during isolation is given in Figure 1. Basically the isolation procedure starts with a mechanical treatment of the tissue. This may contain a segmentation of the cord, chopping into small tissue pieces or scraping of the Wharton’s Jelly. Often the umbilical arteries and vein are removed and discarded before further processing [31,33,39,62] but the perivascular regions, the vessels and the sub endothelium of the vein can also serve as a source of MSC [26–28,40,41,63]. Most of the protocols contain steps of enzymatic digestion of the tissue with several enzymes (e.g., Collagenase I or II, Hyaluronidase and Trypsin) followed by filtration and or centrifugation steps [31,33,39,62,64–67] but explant culture approaches are also described [68–71]. By cutting down the tissue into approximately 0.5 cm$^3$ large pieces and incubating them in appropriate culture media at 37 °C and a humidified atmosphere with 5% CO$_2$, adherent cells will start to grow out of the tissue after approximately 10 days resulting in a confluent culture after two weeks [70].
Freshly isolated UC-derived MSC are mainly fibroblast-like spindle-shaped cells. Although isolated from different compartments of the cord by several isolation techniques, all UC-derived cells are found to meet the minimal criteria for defining multipotent mesenchymal stromal cells as proposed by the ISCT. Thus, besides growing adherent to plastic and exhibiting a multi-lineage differentiation potential, the cells express CD105, CD73 and CD90, and lack the expression of CD45, CD34, CD14 or CD11b, CD79 alpha or CD19 and HLA-DR. An overview of further reported intra- and extra-cellular markers expressed by UC-derived MSC is given in [72].

However, some groups observed varying phenotypes among UC-derived primary cells (see Figure 2). The cultures displayed a broad cell size distribution and when using counterflow centrifugal elutriation (CCE) the cells could be separated according to their size leading to MSC subpopulations that, although sharing the same immunophenotype, displayed significant differences in cell growth and biochemical marker expression [73].

Additionally, when cells isolated from the Wharton’s Jelly were compared to UC arterial- and venous-derived cells significant differences could be observed with regard to proliferative and osteogenic differentiation potential [63]. These results demonstrate the demand for further investigations concerning UC-MSC from different UC-compartments and MSC sub-populations but also raise the question whether the proposed minimal criteria are still sufficiently defined to identify MSC not only from UC but other tissues. In this context, several groups have proposed new surface antigens as universal markers for the identification of MSC from bone marrow and other tissues (reviewed in [74]) such as CD271 [75,76], MSCA-1 [75], SSEA-4 [77,78], and the neural ganglioside
GD2 [79]. To our knowledge MSCA-1 expression in UC-MSC cultures have not been investigated yet. Additionally UC-derived cell populations were found to be negative for CD271 surface antigen expression but express SSEA-4 [63,68]. Furthermore, UC-tissue was shown to harbor a subset of GD2$^+$ cells that exhibit a high clonogenicity as well as proliferation capacity but also a significantly stronger multi-differentiation potential than GD2$^-$ cells, indicating GD2 to be a potential marker useful for the isolation of multipotent MSC from UC-tissue [80].

**Figure 2.** Primary UC-derived cell cultures can contain broad cell size distributions (I < II < III).

4. Differentiation Potential of hAMSC

Besides differentiating into the typical mesenchymal lineages—osteogenic, chondrogenic, adipogenic—hAMSC are also capable to differentiate into cells of all three germ layers: ectoderm (neural, glial), mesoderm (skeletal muscle, endothelial, cardiomyocytic) and endoderm (pancreatic, hepatic).

The osteogenic lineage was one of the first being demonstrated for hAMSC [8,50]. Osteogenic stimulatory media that have been applied (listed in detail in Table 2) are at least supplemented with beta-glycerophosphate, dexamethasone and ascorbat-2-phosphate or ascorbic acid. Mineral deposition upon osteogenic induction has been demonstrated by von Kossa and Alizarinred S staining [1,2,4,8,10,18,21,24,56,81]. Further, alkaline phosphatase activity, as well as staining for alkaline phosphatase and osteocalcin, have been used to proof osteogenic differentiation [2,8,21,56,57,81]. Differentiation efficiency has been further evaluated by PCR for specific markers involved in osteogenesis: the early marker RUNX2, ALP, followed by later markers BGLAP, BMPR1B and BMPR2 [21,24,81]. Stadler *et al.* [21] have demonstrated the impact of four different *in vitro* protocols for osteogenic differentiation – the media according to Pittenger *et al.* [82], In’t Anker *et al.* [8] and Portmann-Lanz *et al.* [50] as well as hMSC Mesenchymal Stem Cell Osteogenic Differentiation Medium (OKit, Lonza). Moreover, hAMSC grown on microcarriers have been demonstrated to differentiate into osteogenic lineage with improved potency [81]. These hAMSC-laden microcarriers were further used for fabricating a macroscopic bone construct in a cylindrical perfusion culture chamber.

Differentiation towards the adipogenic lineage has been achieved with the media listed in Table 2. The formation of multivacuolated cells was proven by Oil Red O staining [1,4,10,18,21,24,56,57] and
the induction of mRNA levels of the adipo-specific genes—PPARgamma, leptin, lipoprotein lipase and fatty acid binding protein aP2—were demonstrated [24,56]. Comparing three different induction media for adipogenic differentiation—the media according to Pittenger et al. [82], In’t Anker et al. [8] as well as Portmann-Lanz et al. [50]—Stadler et al. [21] have reported two of four donors being capable of adipogenic conversion. Paracchini et al. [18] observed morphological changes as well as formation of lipid droplets starting from one week after induction. However, due to considerable donor variability and potentially also due to the use of different protocols, only few hAMSC donors have been shown to be capable of converting into adipocyte-like cells [2,21,24,56].

Chondrogenic differentiation has mostly been demonstrated in pellet cultures using between $2.5 \times 10^5$ and $5.0 \times 10^5$ cells per pellet [1,4,10,56]. For induction of chondrogenic differentiation of hAMSC, transforming growth factor-beta (TGF-b) was supplemented in all 3D-cultures. Detailed media compositions are listed in Table 2. hAMSC differentiated towards the chondrogenic lineage produced abundant extracellular matrix visualized by toluidin or alician blue staining. Further they stained positive for collagen type II and expressed mRNA of SOX-9, SOX-5, SOX-6, BMP-2, BMP-4, BMP receptor (BMPR)-1A, BMPR-1B, BMPR-2, COMP, osteocalcin and aggrecan [1,4,10,23,50,56]. Although 3D-culture may be preferential to support chondrogenic differentiation chondrogenic differentiation has even been demonstrated in a confluent monolayer [23,50].

Myogenic differentiation, another mesodermal lineage, has first been proven by Portmann-Lanz et al. [50], showing expression of the transcription factor MyoD as well as skeletal muscle myosin heavy chain in 15%–35% of induced hAMSC. Confirming these results, Alviano et al. [1] evaluated mRNA expression levels of MyoD and Myogenin after 7 and 14 days, respectively. Immunocytochemical staining further visualized desmin-positive cells after 3 weeks.

Alviano et al. [1] demonstrated also that hAMSC differentiate towards the angiogenic lineage in the matrigel assay, showing increased expression of FLT-1, KDR and ICAM-1. Adding VEGFR even induced expression of CD34 and von Willebrand factor (vWF). However, there are controversial reports regarding angiogenic differentiation. Kim et al. [83] confirmed endothelial differentiation of hAMSC being cultured in EGM-2 demonstrating FLT-1, KDR, Tie-2 and vWF. König et al. [12] demonstrated morphological changes towards endothelial-like appearance, uptake of acetylated low-density lipoprotein as well as formation of endothelial-like structures in the matrigel assay. However, they have not found hAMSC positive for vWF and VE-cadherin and they assumed that hAMSC resisted differentiating into mature endothelial cells. They further analyzed angiogenic differentiation of hAMSC using microarray analysis. Interestingly, pro-angiogenic factors (tenascinC, Tie-2, VEGF-A, CD146, FGF-2) were found to be downregulated, whereas serpin F1, sprout 1 and angioarrestin were upregulated. Supplementing an endothelial cell line culture with the supernatants of endothelially-induced hAMSC supplied network-like structures in the matrigel assay. Kim et al. [83] confirmed these paracrine effects of hAMSC using conditioned media of induced hAMSC in a matrigel-assay with HUVEC.

Cardiomyogenic differentiation of hAMSC has been demonstrated [25,58] and the differentiated cells have already been combined with a scaffold [14]. Undifferentiated hAMSC inherently express cardiac-specific genes and transcription factors: Myosin light chain-2a (MLC-2a), MLC-2v, GATA-4, cardiac troponin (cTn) T, cTnI and the cardiac-specific ion channel genes alpha1c and Kv4.3 [25]. After stimulation with bFGF and activin A, also the cardiac-specific transcription factor Nkx2.5 and
human atrial natriuretic peptide were expressed. Co-culturing hAMSC with rat heart explants revealed integration and transdifferentiation of hAMSC into cardiomyocyte-like cells. Tsuji et al. [58] could increase cardiomyogenic transdifferentiation pretreating hAMSC with interleukin-10 or progesterone and even demonstrated spontaneously beating cells derived from hAMSC when co-cultured with fetal murine cardiomyocytes. Moreover, hAMSC stimulated with S-nitroso-N-acetylpenicillamine towards the cardiomyogenic lineage have been combined with a s-IPN PEtU-PDMS/fibrin scaffold, demonstrating increased cardiac and vascular markers [14].

Due to their multipotency, hAMSC are also able to differentiate into endodermal lineages including hepatocyte-like and pancreatic cells. Undifferentiated hAMSC already express albumin, alpha-fetoprotein, cytokeratin (CK) 18 and alpha1-antitrypsin [53]. Following hepatic induction the expression of these factors was increased and additionally storage of glycogen was clearly detected. Another hepatocyte differentiation protocol was recently published by Paracchini et al. [18]. Beside weak expression of alphal-antitrypsin, increased numbers of cells expressed CK7, albumin and CK19. Furthermore, functionality of cytochrome P450-dependent mixed function oxidase was demonstrated.

Pancreatic differentiation of hAMSC was first demonstrated by Wei et al. [84] although they reported higher differentiation efficiency when using hAEC. Tamagawa et al. [22] designed a three step procedure (details listed in Table 2) demonstrating successful pancreatic differentiation of hAMSC. Morphology changed to rounder epithelial-like cells and many islet-like clusters were observed during the second step applying matrigel. Initial mRNA expression of CK19, Pdx-1 and Nkx2.2 were increased and insulin, glucagon, Isl-1, GLUT-2, GCK, PAX-6, Nkx6-1 and NeuroD were detected after induction. Immunostaining even revealed the proteins insulin, glucagon and somatostatin. Kim et al. [11] recently published the generation of functional insulin-secreting cells derived from hAMSC in a one step procedure. They could confirm that undifferentiated hAMSC already showed low levels of expression of mRNA of pancreatic cell-related genes (NEUROD1, GLUT1, PC2 and GCK). Upon induction, hAMSC showed increased expression of INS, PDX, Nkx6-1, NEUROG3, ISL1, NEUROD1, GLUT1, PC1/3, PC2, GCK, PPY, SST and GCG. Moreover, induced cells secreted insulin as well as c-peptide in a glucose-dependent manner.

hAMSC are further capable to differentiate towards cells derived from the ectodermal lineages. Portmann-Lanz et al. [50] differentiated hAMSC towards the neurogenic lineage revealing subpopulations stained positive for CD133, nestin and neurofilament 200. Phenotypes of neuroglial progenitor cells were observed applying the protocol of Sakuragawa et al. [51]. Unstimulated hAMSC, which express mRNA of the typical neural markers nestin and Musashi1, were induced to increase expression of these genes as well as significantly upregulate beta-tubulin isotype III (TuJ1) and neurofilament-medium (NF-M). Furthermore, also the number of glial fibrillary acidic protein (GFAP) positive cells increased. Tamagawa et al. [85] have demonstrated morphological changes—retracted bodies, long processes, neuron network-like structures—and expression of neuron specific enolase, NF-M, TuJ1, GFAP as well as myelin basic protein after neural induction. Manochantr et al. [57] evaluated a commercially available neural medium—AdvancesSTEM Neural Differentiation Medium (HyClone)—demonstrating sharp, elongated bi-or-tripolar cells expressing MAP-2, TuJ1 and GFAP.
Table 2. Media used for differentiation of hAMSC; Abbreviations: DMEM Dulbecco’s modified Eagles’s medium, LF low glucose, HG high glucose, FCS fetal calf serum, dexamethasone, AAP ascorbic acid or ascorbat-2-phosphate, b-GP beta-glycerophosphate, MEM minimal essential medium eagle, vit D3 1alpha,25dihydroxyvitamin D3, b-ME beta-mercaptoethanol, IBMX 3-isobutyl-1-methylxanthin, IM indomethacin, ITS insulin-transferrin-selenium, TGF-b transforming growth factor-beta, BSA bovine serum albumin, BMP-2 bone morphogenetic protein-2, MCDB medium complete with trace elements, LA linoleic acid, bFGF basic fibroblast growth factor, VEGF vascular endothelial growth factor, IGF-1 insulin like growth factor-1, EGF epidermal growth factor, HGF hepatic growth factor, NEAA nonessential amino acid, IMDM Is FRH¶V modified DMEM, DMSO dimethyl sulfoxide, KCl potassium chloride, PDGF platelet-derived growth factor, AMP adenosine monophosphate.

| lineage      | reference               | media description                                                                 | protocol                      |
|--------------|-------------------------|-----------------------------------------------------------------------------------|-------------------------------|
| osteogenic   | Pittenger [82]          | DMEM-LG, 10% FCS, 10⁻⁷ M dexta, 50 µM AAP, 10 mM b-GP, 10 mM vit D3               | b-GP was added from day 7 on, 21 days |
|              | In’t Anker [8]          | alphaMEM, 10% FCS, 10⁻⁷ M dexta, 50 µg/mL AAP, 5 mM b-GP                        |                               |
|              | Portmann-Lanz [50]      | DMEM-HG, 10% FCS, 10 µmol/L dexta, 50 µg/mL AAP, 10 mol/L b-GP, 10 nmol/L vit D3 | 18–21 days                    |
|              | Alviano [1]             | DMEM, 10% FCS, 10⁻⁸ M dexta, 0.2 mM AAP, 10 mM b-GP                             | 21–28 days                    |
|              | Sudo [56]               | DMEM-HG, 10% FCS, 10⁻⁷ M dexta, 0.5 µM AAP, 10 mM b-GP                          | 28 days                       |
|              | Chen [81]               | DMEM, 10% FCS, 100nM dexta, 0.1 µM AAP, 10 mM b-GP, 5 × 10⁻⁵ M b-ME hMSC          | induction on day 8 for 20 days |
|              | Bilic [2], Diaz-Prado   | Osteogenic Differentiation Medium (Lonza)                                         | 14 (Bilic) or 21 days         |
|              | [4], Paracchini [18]    | MesenCult Osteogenic Stimulatory Kit (OKit, Stemcell Technologies)               | (Diaz-Prado, Paracchini)      |
|              | Stadler [21], Wolbank   | NH Osteodiff medium (Miltenyi)                                                   | 21 (Wolbank) or 28 (Stadler)  |
|              | [24]                    |                                                                                   |                               |
|              | Manochantr [57], Kang   |                                                                                   |                               |
|              | [10]                    |                                                                                   |                               |
| adipogenic   | Pittenger [82]          | medium 1: DMEM-HG, 10% FCS, 0.5 mM IBMX, 0.1 µM dexta, 10 µg/mL insulin, 100 µM IM, | medium 1: 48-72h, repeated cycles; 28 days (Stadler) |
|              | In’t Anker [8]          | medium 2: DMEM-HG, 10% FCS, 0.5 µg/mL insulin                                     |                               |
|              | Portmann-Lanz [50]      | alphaMEM, 10% FCS, 0.5 mM IBMX, 10⁻⁷ M dexta, 1.60 µM insulin, 50 µM IM, 50 µg/mL AAP | 21 (In’t Anker) or 28 days (Stadler) |
|              |                         | DMEM-HG, 10% FCS, 0.5 mmol/L                                                     | 18–21d (Portmann-Lanz, Wolbank) or 28 days (Stadler) |
Table 2. Cont.

| lineage      | reference    | media description                                                                 | protocol |
|--------------|--------------|----------------------------------------------------------------------------------|----------|
|              | Alviano [1]  | DMEM, 10% FCS, 0.5 mM IBMX, 10⁻⁶ M dexa, 10 μg/mL insulin, 200 μM IM               | 14–21 days |
|              | Sudo [56]    | medium 1: DMEM-HG, 10% FCS, 0.5 mM IBMX, 1 μM dexa, 10 ng/mL insulin, 0.2 mM IM     | medium 1: 3 days, medium 2: 3 days; repeated cycles for 24–30 days |
|              | Kang [10]    | DMEM-LG, 10% FCS, 1 mM dexa, 0.5 mM IBMX, 1 μg/mL insulin, 200 μM IM               | 21 days  |
|              | Diaz-Prado [4], Paracchini [18] | Adipogenic Differentiation Medium (Lonza)                                           | 21 days  |
|              | Bilic [2], Manochantr [57] | NH Adipodiff medium (Miltenyi)                                                     | 21 days  |
| chondrogenic | Sudo [56]    | alphaMEM, 3.5 g/mL glucose, 1% ITS, 100 μg/mL sodium pyruvate, 0.2 mM AAP, 10⁻⁷ M dexa, 10 ng/mL TGF-b3 | 28–30 days, pellet culture |
|              | Alviano [1]  | DMEM, 1 mM sodium pyruvate, 0.1 mM AAP, 10⁻⁷ M dexa, 10 ng/mL TGF-b3, 6.25 μg/mL insulin, 6.25 μg/mL linoleic acid, 0.35 mM proline, 1.25 mg/mL BSA, 1/1.000 monotiglycerol | 21–28 days, pellet culture |
|              | Diaz-Prado [4] | medium 1: DMEM, 15% FCS, 5 mg/mL AAP                                                | first 2 days medium 1, followed by 21 days medium 2; pellet culture |
|              | Kang [10]    | NH chondrogenic medium (Miltenyi)                                                   | 21 days, pellet culture |
|              | Portmann-Lanz [50] | DMEM-HG, 1% FCS, 100 ng/mL AAP, 10 ng/mL TGF-b1, 6.25 μg/mL insulin                | 18–21 days, after confluence, 14 days |
|              | Wei [23]     | DMEM, 10% FCS, 200 ng/mL rhuBMP-2                                                  | 18–21 days, after confluence, 14 days |
| myogenic     | Portmann-Lanz [50] | DMEM-HG, 10% FCS, 50 μmol/L hydrocortison, 0.1 μmol/L dexa, DMEM, 5% FCS, 40% MCDB-201, 10⁻⁸ M dexa, ITS-LA*BSA 1×, 10⁻⁴ M AAP, 10 ng/mL bFGF, 10 ng/mL VEGF, 10 ng/mL IGF-1 | 18–21 days, after confluence, 14 days |
|              | Alviano [1]  | DMEM, 5% FCS, 40% MCDB-201, 10⁻⁸ M dexa, ITS-LA*BSA 1×, 10⁻⁴ M AAP, 10 ng/mL bFGF, 10 ng/mL VEGF, 10 ng/mL IGF-1 | 21 days  |
Table 2. Cont.

| Source                  | Medium/Conditions                                                                 | Duration/Notes                                                                 |
|-------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Bilic [2]               | DMEM-HG, 10% FCS, 5% horse serum, 50 μM hydrocortison, 0.1 μM dexamethasone       | 7 days, followed by matrigel assay                                              |
|                        |                                                                                 | at least 10 days, followed by matrigel assay                                    |
| angiogenic              |                                                                                 |                                                                                |
| Alviano [1]             | DMEM, 2% FCS, 50 ng/mL VEGF                                                    | 7 days                                                                            |
| König [12]              | Endothelial Growth Medium-2 (Lonza) +/- 50 ng/mL VEGF                          | 10–20 days, followed by matrigel assay                                           |
| Kim SW [83]             | Endothelial Growth Medium-2 (Lonza)                                            |                                                                                 |
| cardiomogenic           |                                                                                 |                                                                                |
| Zhao [25]               | DMEM, 10% FCS, 2nd d addition of 10 ng/mL bFGF or 50 ng/mL activin A            | (a) 7 days after addition of growth factors; (b) coculture with rat heart explants |
|                        |                                                                                 | with fetal murine cardiomyocytes seeded on s-IPN                                |
|                        |                                                                                 | PRu-PDMS/fibrin scaffold, 14 days                                               |
|                        |                                                                                 |                                                                                |
| hepatic                 |                                                                                 |                                                                                |
| Tsuji [58]              | unknown                                                                         |                                                                                |
|                        | DMEM, 10% FCS, 10 ng/mL EGF                                                   |                                                                                |
| Lisi [14]               | 55 μM b-ME, d2-4: + 0.4 μM S-nitroso-N-acetylsalicilamide                        |                                                                                |
| Tamagawa [53]           | alphaMEM, 10% FCS, 0.1 mmoL/L dexamethasone, 20 ng/mL hEGF, 10 ng/mL hEGF,    | 21 days                                                                          |
|                        | 10 ng/mL oncostatin                                                            |                                                                                |
| Paracchini [18]         | medium 1: DMEM, 10% FCS, 1% NEAA, 55 μM b-ME, 10 ng/mL EGF                     | first 8 days medium 1, followed by medium 2 until day 21                        |
|                        | medium 2: IMEM, 10% FCS, 10⁻⁷ M dexamethasone, 1% NEAA, 55 μM b-ME, 10 ng/mL EGF |                                                                                |
| pancreatic              |                                                                                 |                                                                                |
| Wei [84]                | DMEM, N2 supplement, 0.1 mmoL/L nicotinamide                                    | first 2 days medium 1, medium 2 and 3 in matrigel                              |
| Tamagawa [22]           | medium 1: DMEM-HG, 10⁻⁶ M retinoic acid                                        |                                                                                |
|                        | medium 2: DMEM-LG, 10% FCS, 1 x N2 supplement, 10 mM nicotinamide,              |                                                                                |
|                        | 20 ng/mL hEGF                                                                  |                                                                                |
|                        | medium 3: DMEM-LG, 10 mM exendin-4                                              |                                                                                |
|                        | medium 1: DMEM-HG, 10% FCS                                                      |                                                                                |
| Kim J [11]              | 10 mM nicotinamide, 4 nmol activin A, 10 nmol GLP-1                            | first 7 days medium 1, followed by 14 days medium 2                             |
|                        | medium 2: DMEM-LG, 10% FCS, 10 mM nicotinamide, 4 nmol activin A, 10 nmol GLP-1|                                                                                |
| neural                  |                                                                                 |                                                                                |
| Portmann-Lanz [50]      | DMEM-HG, 10% FCS, 30 μmol/L all trans retinoic acid                            | 18–21 days                                                                      |
|                        | DMEM, 100 μM butylated hydroxianisole, 10 μM forskolin, 2% DMSO, 5 U/mL heparin, 5 nM |                                                                                |
| Sakuragawa [51]         | 25 mM KCl, 2 mM valproic acid, 1 x N2 supplement, 10 ng/mL bFGF, 10 ng/mL PDGF |                                                                                |
Table 2. Cont.

| Tamagawa [85] | medium 1: alphaMEM, 10% FCS, 1 × N2 supplement, 10 ng/mL bFGF, 10 ng/mL EGF | 48 h medium 1, followed by 96 h medium 2 |
| medium 2: alphaMEM, 1 μM all trans retinoic acid, 200 μM butylated hydroxianisole, 1 × N2 supplement, 1 mM dibutyryl cyclic AMP, 0.5 mM IBMX | followed by 96 h medium 2 |
| Manochantr [57] | AdvancesSTEM Neural Differentiation Medium (HyClone) | until neural like cells were observed |

5. Differentiation potential of UC-MSC

Similar to MSC from BM and other sources, UC-derived MSC, as widely investigated by several groups, could be shown to differentiate into adipocytes [26,27,30,33,38,40,63–65,67,68,70,86–108], chondrocytes [27,29,33,38,40,63,68,70,86–91,93,94,96,98,99,103,104,106,108,109], and osteocytes [26–28,30,33,38,40,41,63–65,67,68,73,86–106,108,110–114]. An overview of the reported differentiation potential of UC-derived MSC is given in Table 3.

Besides the “classical” mesenchymal lineages differentiation of UC-MSC into cells of all three germ layers has been described. Thus it has been shown that UC-derived MSC could be differentiated into functional endothelial progenitor cells after induction with VEGF and bFGF [93,101,115]. Furthermore, vessel-like structure formation and even differentiation into skeletal myocyte-like cells could be observed [30,86,93].

Table 3. Overview of the reported differentiation potential of UC-derived MSC

| lineage          | reference |
|------------------|-----------|
| osteogenic       | [26–28,30,33,38,40,41,63–65,67,68,73,86–106,108,110–114] |
| adipogenic       | [26,27,30,33,38,40,63–65,67,68,70,86–108] |
| chondrogenic     | [27,29,33,38,40,63,68,70,86–91,93,94,96,98,99,103,104,106,108,109] |
| myogenic         | [30] |
| angiogenic       | [86,93,101,115] |
| cardiomyogenic   | [38,68,92,96,116–118] |
| hepatic          | [109,119,120] |
| pancreatic       | [121–124] |
| neural           | [31–33,35,36,65,68,91,104,125–128] |

For the cardiomyogenic differentiation of UC-MSC 5-azacytidine was shown to be a potent agent to induce differentiation into cardiomyocyte-like cells shown by changing morphology to a typical cardiac phenotype and the expression of specific cardiac markers like N-cadherin, cardiac troponin, desmin, alpha sarcomeric actin, and myosin heavy chain [38,68,92,116,117]. Additionally
Sphingosine-1-phosphate (S1P) was shown to induce cardiomyogenic differentiation of UC-derived MSC, as well [118]. In response to S1P UC-MSC displayed a cardiomyocyte-like morphology and expressed alpha-actinin and myosin heavy chain proteins. Furthermore, differentiated cells displayed a cardiomyocyte-like action potential and voltage gated currents when patch clamping recording was applied. However, other groups could not detect cardiac marker expression after induction of cardiogenic differentiation of UC-MSC and to our knowledge, only one group reported slightly spontaneous beating of differentiated cells after 21 days of culture [96,116].

Studies by several groups indicate that UC-derived MSC can also differentiate into cells of the endodermal lineage. Thus it could be shown that UC-MSC, when applying appropriate culture conditions, can differentiate into hepatocyte-like cells [109,119,120]. After induction with several growth factors, like hepatocyte growth factor (HGF), bFGF, or FGF-4 cells displayed a hepatocyte-like morphology and expressed several hepatic markers like albumin, alpha-fetoprotein, cytokeratin-19, connexin-32, and dipeptidyl peptidase IV. Furthermore, differentiated cells displayed typical hepatocyte-specific functions, including albumin secretion, urea uptake, glycogen storage, and low-density lipoprotein uptake. Noteworthy first results indicate that UC-MSC do not lose their in vitro immune privilege after differentiation underlining that the UC-tissue is a favorable source of MSC for clinical applications [120]. However, it should be mentioned that some authors pointed out that they did not observe some important characteristics of functional liver cells in hepatic differentiated UC-MSC suggesting that these cells can only be differentiated into immature hepatocytes [119].

Regarding other cell types of the endodermal lineage UC-MSC could also be shown to form islet-like cell clusters secreting insulin in response to glucose challenge and expressing pancreatic beta-cell development-related genes like PDX-1 after induction with appropriate agents like nicotinamide or beta-mercaptoethanol [121–124]. Additionally it could be shown that differentiated insulin-producing UC-derived cells could alleviate hyperglycemia in diabetic mice [122].

Investigating the potential of UC-derived MSC to differentiate into cells of the ectodermal lineage several groups reported differentiation into neural-like cells [31–33,35,36,65,68,91,104,125–128]. Upon stimulation with potent agents like b-FGF, or retionic acid morphological changes and neuro-specific marker expression, like nestin, β-tubulin III, or neurofilament M, could be observed on the mRNA as well as protein level.

The published data gives strong evidence that UC-derived MSC are multipotent cells which are capable of differentiating into cells of all three germ layers. However, since UC-MSC are a rather heterogenic population, especially when isolated from whole UC-tissue or the WJ, it still remains to be investigated whether all or only cells from a distinct compartment of the cord are capable of differentiating into all cell types mentioned above. For instance Sarugaser et al. showed that perivascular-derived UC-cells displayed a high osteogenic differentiation potential, but could not be differentiated into neuron-like cells [41]. In contrast Suzdal’tseva et al. reported an only poor osteogenic potential of UC vein subendothelial tissue-derived cells [99] and Karahuseyinoglu et al. could identify sub-populations in WJ-derived cell cultures from which one, predominately expressing cytokeratin, could not be differentiated into neuron-like cells [33].
6. Immunological properties of hAMSC and UC-MSC

Besides their multi-lineage differentiation potential, MSC were also found to be only weakly immunogenic and exhibit immunomodulatory properties which means that they escape immunological defense mechanisms and are able to suppress several functions of immunocompetent cells. It has been reported that hAMSC and UC-MSC possess an immunoprivileged status as well, which is in part due to the expression of low to moderate levels of surface MHC-I, and the presence of low or even absent levels of MHC II and costimulatory molecules (e.g., CD40, CD80, CD86) [6,8,11,19,55,65,129–131].

Implantation of hAMSC into animals resulted in successful and persistent engraftment in multiple organs and tissues. hAMSC survived for at least two months in xenotransplanted myocardial infarcts in rat hearts, showing low immunogenicity [25]. Tsuji et al. [58] found hAMSC transdifferentiated towards the cardiomyogenic lineage surviving for more than 4 weeks after implantation into infarcted myocardium in non-immunosuppressed rats. Similarly, implantation of hAMSC into the subfacial space of the abdominal muscle in mice and intraperitoneal or intravenous injection into neonatal swine did not lead to transplant rejection during the observed experimental period of 35 and 61 days, respectively [23,132].

Implantation of porcine UC-MSC into rat brains resulted in engraftment and proliferation of the cells for up to eight weeks without immune rejection or the formation of teratomas [133]. Furthermore, when human UC-derived MSC were transplanted into Parkinson’s disease (PD) model rats, the cells did not induce the formation of brain tumors or immune rejections but mitigated induced motor deficits [39]. Further studies could reveal survival and proliferation of xenotransplanted UC-derived cells for five and eight weeks, respectively [134,135].

In vitro, immunological tolerance was demonstrated by low or absent allogenic reaction, coculturing unstimulated allogenic peripheral blood mononuclear cells (PBMC) or other immune cells and hAMSC [49,55] and UC-MSC [129,130,136,137], respectively.

Various in vitro studies have been conducted to define the immunomodulatory potential of MSC and the underlying mechanisms are still not fully understood. In this context it is still under discussion whether the regulatory effects depend on cell-to-cell contacts or are mediated by soluble factors. Several groups have used in vitro co-culture setups to analyze the inhibitory effects of hAMSC and UC-MSC on the proliferation of PBMC or other immunocompetent cells stimulated by mixed lymphocyte reaction or mitogens (e.g., phytohemagglutinin (PHA)) which was found to be inhibited by hAMSC and UC-MSC in a dose-, cell-contact-dependent as well as factor-mediated manner [129–131,136–140]. Interestingly, cryopreservation of hAMSC significantly decreased the immunomodulatory potential, which could, however, not be linked to changes in the expression of MHC-I and -II [55]. With regard to soluble factors, several groups have reported that MSC constitutively or upon stimulation secrete a variety of mediators among which prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO) and nitric oxide (NO) seem to be key molecules in immune regulation. Chen et al. used transwell co-cultures of stimulated PBMC with UC-MSC to show that immunosuppression was mainly mediated through a PGE2-dependent mechanism since PGE2-production was enhanced upon co-cultivation and blocking of PEG2 biosynthesis completely abolished immunosuppressive effects [129]. Furthermore, studies by Cutler et al. implicate monocytes as a key intermediary in UC-MSC–induced suppression of T cell proliferation since function and the
allostimulatory capacity of monocytes are downregulated, which is in part mediated by UC-MSC-derived PGE2 [141].

Kang et al. confirmed the inhibitory effect of hAMSC on mitogen-stimulated PBMC [10]. IFNgamma and IL-17 produced by PBMC was shown to decrease, whereas interleukin (IL)-10 increased. Concomitantly hAMSC increased levels of secreted TGF-b, HGF, PGE2 and IDO. Pretreatment of hAMSC with IFNgamma was shown to enhance their anti-proliferative effects on stimulated PBMC and T cells [13]. Whereas CD105 and surface density of CD90 decreased, CD54, HLA-DR, CD40, as well as the inhibitory co-stimulatory molecules PD-L1 and PD-L2 were upregulated. Coculturing PBMC and IFNgamma-treated hAMSC revealed downregulation of chemokines (RANTES, IP-10, MIG, MIP-1alpha, MIP-1beta, MCP-1), cytokines (IL-21, IL-12p70, IL-9, IFNgamma, IL-13, TNFalpha, IL-17A, IL-12/IL23p40, IL-4, IL-10) and sFAS-L as well as sCD40L, whereas IL-11, IL-6, IL-8 and LIF were upregulated. Quite similar results were obtained when analyzing the secretome of stimulated T cell in presence of hAMSC (except for MCP-1 and IP-10 which were increased). Two subpopulations of hAMSC have been described which differently express MHC-II, CD45, CD14 and CD86, thus resulting in both suppressive and stimulatory properties [49]. The stimulatory effect on anti-CD3-primed T cells at low concentrations was reported to be attributed to the HLA-DR positive subpopulation. These cells were shown to have characteristics similar to human monocytes but have proven to be of fetal origin.

Besides T cells, MSC were found to influence several other immune cells. Che et al. could show that UC-MSC significantly suppressed the proliferation, differentiation, and immunoglobulin secretion of B cells in vitro [142]. Furthermore, hAMSC have been shown to suppress differentiation and maturation of monocytes into dendritic cells (DC), arresting them in the G0 phase of the cell cycle. The presence of hAMSC inhibited the production of inflammatory cytokines including TNFalpha, CXCL10, CXCL9 and CCL5 in co-cultured monocytes [15]. Taken together these effects resulted in a diminished capacity of DC to activate T cells. Moreover, a comparison of hAMSC to human adipose tissue derived stem cells [143] demonstrated superiority of hAMSC regarding the inhibition of stimulated monocytes to differentiate into DC. In the described cell contact independent co-culture setting, high levels of PGE2 and HGF were found. However, this superiority of hAMSC might not be related merely to their early developmental stage, since bone marrow derived cells similarly suppress DC differentiation [144–146], whereas multipotent cord blood derived cells do not share these properties [147].

Moreover, Tsuji et al. [58] not only found surviving hAMSC transdifferentiated towards the cardiomyogenic lineage at least 4 weeks after implantation into rat infarcted myocardium, they also provide an in vivo study on the immunomodulation [58]. They found that retreatment of hAMSC with the anti-inflammatory cytokine IL-10 increased the level of HLA-G expressed on hAMSC, which may play a role in initial processes of tolerance. Furthermore, regulatory T cells, defined as FOXP3 positive lymphocytes, were detected adjacent to implanted hAMSC into infarcted myocardium of rat hearts, which may be involved in maintenance of tolerance.
7. Immortalization of hAMSC and UC-MSC

Applying MSC for cell therapy, higher cell numbers are required. Furthermore, well characterized cell lines, constantly growing while maintaining their typical properties, are highly valuable for research. Immortalization is one opportunity to fulfill this requirement. Wolbank et al. [24] could successfully establish two cell lines derived from hAMSC using a retroviral transfection system for introduction of hTERT. hTERT overexpression in hAMSC maintained fibroblastic morphology, surface expression of most hematopoietic and mesenchymal stem cell marker as well as adipogenic and osteogenic differentiation potential. Furthermore, immunological properties were similar to parental cells and no chromosomal abnormalities or tumorigenic conversion was observed.

As recently reported, also immortalized MSC from UC vein and Wharton’s jelly have been established [148,149]. First analysis of these UC-MSC expressing ectopic hTERT revealed that the findings regarding immortalized hMSC from common tissues like bone marrow and amnion are comparable to preliminary data collected from immortalized UC-MSC. The modified cells increased their population doubling capacity up to more than 100 PD with no morphological or karyotypic alterations [149]. Flow cytometric analysis of the surface molecules revealed expression of MSC specific markers (CD13, CD29, CD105) and lack the expression of CD 34, CD45, HLA-DR. Furthermore, these cells were proven to express a set of genes like Oct-4, Nanog, ZFX, Bmi-1 and Nucleostemin which are known to be associated with their self-renewal capacity [148]. Immunologic analysis show maintenance of the MSC immunotolerance as well as the absence of any tumorigenic conversion in vitro or in nude mice during a period of 2 weeks [149]. Furthermore, the differentiation of immortalized UC-MSC in hepatocyte-like cells and subsequent analysis of liver specific markers showed that these MSC also maintain their multipotent differentiation potential similar to the isolated parental cells in early passages.

However, less is known about the influence of such modifications to the entire expression patterns and the impact on hMSC behavior. Such suggestions based on the fact that immortalization via common transfection methods based on randomized insertion of the hTERT gene into the genome of hMSC. Although immortalized hMSC exhibit near limitless potential, considering the application of such cells in clinical trials require either the localization of the exact positions of the transgenes or transfection methods which allow exact gene targeting.

8. Prospective Clinical Applications: Current State and Outlook

Isolated from biologic waste, ethically non-problematic, stem cells from full-term umbilical cord tissue and amniotic membrane are easily available and may present an attractive completion to other classically established stem cells (e.g., from bone marrow) in different clinical approaches. Since it has been shown in numerous papers that MSC have the ability to down-regulate immune response and support tissue repair mechanisms their use has been widespread for the treatment of many different diseases. Currently performed studies often apply MSC from bone marrow (39 studies in different stages, several involving a combination therapy with drugs). Over the last decade’s 125 clinical trials has been documented using MSC from bone marrow, 43 studies for UC-MSC (3 for MSC from
Wharton’s jelly respectively) and only one is documented for MSC isolated from amniotic membrane [150].

The application of UC-MSC in the documented studies include treatment of Graft vs. Host Disease (GvHD), hepatic cirrhosis, colitis ulcerosa, type 1 diabetes and treatment of diabetic foot wounds, cardiomyopathy, Alzheimer disease, different autoimmune diseases e.g., multiple sclerosis and muscular dystrophy, neuromyelitis optica and rheumatoid arthritis.

UC-MSC have for instance been applied in the treatment of 160 patients after myocardial infarction in a double-blind, placebo-controlled, multicenter phase 2 trial (by Navy General Hospital, Beijing, completed July 2012) [151]. Several papers report on differentiation of UC-MSC into cardiomyocyte-like cells [38, 152, 153], but functionality of these derived cells is also controversially discussed [96, 154].

Twenty-two clinical trials use MSC for the treatment of Graft vs. Host Disease (GvHD) whereas the most recent studies started recruiting patients in 2012. UC-MSC have also been applied for the treatment of Alzheimer disease (NCT01547689) and in HIV patients (NCT01213186). Successful and promising preclinical studies on UC-MSC and hAMSC performed to date and their diverse properties offer these cells the possibility for future clinical use in the treatment of various diseases. Till then some major obstacles, such as translation from research to GMP-scale, market authorization and clinical application will need to be resolved.

9. Conclusion

Taken together, the results of published data and clinical trials on MSC have proven to provide great potential for different therapeutic applications. Due to their young age, UC-MSC and hAMSC possess high proliferative capacity and expansion potential; thus, the \textit{in vitro} expansion process can be reduced with regard to time and passage number. In addition, a reduction of labor intensive work risks of contamination and damages (e.g., inadvertant epigentic modifications) during \textit{in vitro} expansion can be achieved. The combination of retaining multilineage differentiation potential with their immunmodulatory properties make MSC from umbilical cord tissue and amnion promising cell therapeutics.

Conflict of Interest

The authors declare no conflict of interest.

References and Notes

1. Alviano, F.; Fossati, V.; Marchionni, C.; Arpinati, M.; Bonsi, L.; Franchina, M.; Lanzoni, G.; Cantoni, S.; Cavallini, C.; Bianchi, F.; et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells \textit{in vitro}. \textit{BMC. Dev. Biol.} \textbf{2007}, \textit{7}, 11.

2. Bilic, G.; Zeisberger, S.M.; Mallik, A.S.; Zimmermann, R.; Zisch, A.H. Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy. \textit{Cell Transplant.} \textbf{2008}, \textit{17}, 955–968.
3. Cargnoni, A.; Ressel, L.; Rossi, D.; Poli, A.; Arienti, D.; Lombardi, G.; Parolini, O. Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis. *Cytotherapy* **2012**, *14*, 153–161.

4. Diaz-Prado, S.; Muinos-Lopez, E.; Hermida-Gomez, T.; Rendal-Vazquez, M.E.; Fuentes-Boquete, I.; de Toro, F.J.; Blanco, F.J. Multilineage differentiation potential of cells isolated from the human amniotic membrane. *J. Cell Biochem.* **2010**, *111*, 846–857.

5. Diaz-Prado, S.; Muinos-Lopez, E.; Hermida-Gomez, T.; Cicione, C.; Rendal-Vazquez, M.E.; Fuentes-Boquete, I.; de Toro, F.J.; Blanco, F.J. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. *Differentiation* **2011**, *81*, 162–171.

6. Evangelista, M.; Soncini, M.; Parolini, O. Placenta-derived stem cells: New hope for cell therapy? *Cytotechnology* **2008**, *58*, 33–42.

7. Ilancheran, S.; Moodley, Y.; Manuelpillai, U. Human fetal membranes: A source of stem cells for tissue regeneration and repair? *Placenta* **2009**, *30*, 2–10.

8. In ’t Anker, P.S.; Scherjon, S.A.; Kleijburg-van der Keur, C.; de Groot-Swings, G.M.; Claas, F.H.; Fibbe, W.E.; Kanhai, H.H. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells* **2004**, *22*, 1338–1345.

9. Insausti, C.L.; Blanquer, M.; Bleda, P.; Iniesta, P.; Majado, M.J.; Castellanos, G.; Moraleda, J.M. The amniotic membrane as a source of stem cells. *Histol. Histopathol.* **2010**, *25*, 91–98.

10. Kang, J.W.; Koo, H.C.; Hwang, S.Y.; Kang, S.K.; Ra, J.C.; Lee, M.H.; Park, Y.H.; Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells. *J. Vet. Sci.* **2012**, *13*, 23–31.

11. Kim, J.; Park, S.; Kang, H.M.; Ahn, C.W.; Kwon, H.C.; Song, J.H.; Lee, Y.J.; Lee, K.H.; Yang, H.; Baek, S.Y.; *et al.* Human insulin secreted from insulinogenic xenograft restores normoglycemia in type i diabetic mice without immunosuppression. *Cell Transplant.* **2012**, doi: 10.3727/096368912X636803.

12. König, J.; Huppertz, B.; Desoye, G.; Parolini, O.; Frohlich, J.D.; Weiss, G.; Dohr, G.; Sedlmayr, P.; Lang, I. Amnion-derived mesenchymal stromal cells show angiogenic properties but resist differentiation into mature endothelial cells. *Stem Cells Dev.* **2012**, *21*, 1309–1320.

13. Kronsteiner, B.; Wolbauer, S.; Peterbauer, A.; Hackl, C.; Redl, H.; van, G.M.; Gabriel, C. Human mesenchymal stem cells from adipose tissue and amnion influence t-cells depending on stimulation method and presence of other immune cells. *Stem Cells Dev.* **2011**, *20*, 2115–2126.

14. Lisi, A.; Briganti, E.; Ledda, M.; Losi, P.; Grimaldi, S.; Marchese, R.; Soldani, G., A combined synthetic-fibrin scaffold supports growth and cardiomyogenic commitment of human placental derived stem cells. *PLoS One* **2012**, *7*, e34284.

15. Magatti, M.; De, M.S.; Vertua, E.; Nassauto, C.; Albertini, A.; Wengler, G.S.; Parolini, O. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. *Cell Transplant.* **2009**, *18*, 899–914.

16. Manuelpillai, U.; Moodley, Y.; Borlongan, C.V.; Parolini, O. Amniotic membrane and amniotic cells: Potential therapeutic tools to combat tissue inflammation and fibrosis? *Placenta* **2011**, *32* (*Suppl. 4*), S320-S325.

17. Miki, T.; Strom, S.C. Amnion-derived pluripotent/multipotent stem cells. *Stem Cell Rev.* **2006**, *2*, 133–142.
18. Paracchini, V.; Carbone, A.; Colombo, F.; Castellani, S.; Mazzucchelli, S.; Gioia, S.D.; Degiorgio, D.; Seia, M.; Porretti, L.; Colombo, C.; et al. Amniotic mesenchymal stem cells: A new source for hepatocyte-like cells and induction of cfr expression by coculture with cystic fibrosis airway epithelial cells. J. Biomed. Biotechnol. 2012, 2012, 575471.
19. Parolini, O.; Alviano, F.; Bagnara, G.P.; Bilic, G.; Buhring, H.J.; Evangelista, M.; Hennerbichler, S.; Liu, B.; Magatti, M.; Mao, N.; et al. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international workshop on placenta derived stem cells. Stem Cells 2008, 26, 300–311.
20. Roubelakis, M.G.; Trohatou, O.; Anagnou, N.P. Amniotic fluid and amniotic membrane stem cells: Marker discovery. Stem Cells Int. 2012, 2012, 107836.
21. Stadler, G.; Hennerbichler, S.; Lindenmair, A.; Peterbauer, A.; Hofer, K.; van, G.M.; Gabriel, C.; Redl, H.; Wolbank, S. Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro. Cytotherapy. 2008, 10, 743–752.
22. Tamagawa, T.; Ishiwata, I.; Sato, K.; Nakamura, Y. Induced in vitro differentiation of pancreatic-like cells from human amnion-derived fibroblast-like cells. Hum. Cell 2009, 22, 55–63.
23. Wei, J.P.; Nawata, M.; Wakitani, S.; Kametani, K.; Ota, M.; Toda, A.; Konishi, I.; Ebara, S.; Nikaido, T. Human amniotic mesenchymal cells differentiate into chondrocytes. Cloning Stem Cells 2009, 11, 19–26.
24. Wolbank, S.; Stadler, G.; Peterbauer, A.; Gillich, A.; Karbiener, M.; Streubel, B.; Wieser, M.; Katinger, H.; van, G.M.; Redl, H.; et al. Telomerase immortalized human amnion- and adipose-derived mesenchymal stem cells: Maintenance of differentiation and immunomodulatory characteristics. Tissue Eng. Part A 2009, 15, 1843–1854.
25. Zhao, P.; Ise, H.; Hongo, M.; Ota, M.; Konishi, I.; Nikaido, T. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation 2005, 79, 528–535.
26. Covas, D.T.; Siufi, J.L.; Silva, A.R.; Orellana, M.D. Isolation and culture of umbilical vein mesenchymal stem cells. Braz. J. Med. Biol. Res. 2003, 36, 1179–1183.
27. Panepucci, R.A.; Siufi, J.L.; Silva, W.A., Jr.; Proto-Siquiera, R.; Neder, L.; Orellana, M.; Rocha, V.; Covas, D.T.; Zago, M.A. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 2004, 22, 1263–1278.
28. Romanov, Y.A.; Svintsitskaya, V.A.; Smirnov, V.N. Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate msc-like cells from umbilical cord. Stem Cells 2003, 21, 105–110.
29. Bailey, M.M.; Wang, L.; Bode, C.J.; Mitchell, K.E.; Detamore, M.S. A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng 2007, 13, 2003–2010.
30. Conconi, M.T.; Burra, P.; Di Liddo, R.; Calore, C.; Turetta, M.; Bellini, S.; Bo, P.; Nussdorfer, G.G.; Parnigotto, P.P. Cd105(+) cells from wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int. J. Mol. Med. 2006, 18, 1089–1096.
31. Fu, Y.S.; Cheng, Y.C.; Lin, M.Y.; Cheng, H.; Chu, P.M.; Chou, S.C.; Shih, Y.H.; Ko, M.H.; Sung, M.S. Conversion of human umbilical cord mesenchymal stem cells in wharton's jelly to dopaminergic neurons in vitro: Potential therapeutic application for parkinsonism. Stem Cells 2006, 24, 115–124.
32. Fu, Y.S.; Shih, Y.T.; Cheng, Y.C.; Min, M.Y. Transformation of human umbilical mesenchymal cells into neurons in vitro. *J. Biomed. Sci.* **2004**, *11*, 652–660.

33. Karahuseyinoglu, S.; Cinar, O.; Kilic, E.; Kara, F.; Akay, G.G.; Demiralp, D.O.; Tukun, A.; Uckan, D.; Can, A. Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. *Stem Cells* **2007**, *25*, 319–331.

34. Lund, R.D.; Wang, S.; Lu, B.; Girman, S.; Holmes, T.; Sauve, Y.; Messina, D.J.; Harris, I.R.; Kihm, A.J.; Harmon, A.M.; *et al.* Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. *Stem Cells* **2007**, *25*, 602–611.

35. Ma, L.; Feng, X.Y.; Cui, B.L.; Law, F.; Jiang, X.W.; Yang, L.Y.; Xie, Q.D.; Huang, T.H. Human umbilical cord wharton's jelly-derived mesenchymal stem cells differentiation into nerve-like cells. *Chin. Med. J. (Engl)* **2005**, *118*, 1987–1993.

36. Mitchell, K.E.; Weiss, M.L.; Mitchell, B.M.; Martin, P.; Davis, D.; Morales, L.; Helwig, B.; Beerenstrauch, M.; Abou-Easa, K.; Hildreth, T.; *et al.* Matrix cells from wharton's jelly form neurons and glia. *Stem Cells* **2003**, *21*, 50–60.

37. Schmidt, D.; Mol, A.; Odermatt, B.; Neuenschwander, S.; Breymann, C.; Gossi, M.; Genoni, M.; Zund, G.; Huerstrup, S.P. Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. *Tissue. Eng.* **2006**, *12*, 3223–3232.

38. Wang, H.S.; Hung, S.C.; Peng, S.T.; Huang, C.C.; Wei, H.M.; Guo, Y.J.; Fu, Y.S.; Lai, M.C.; Chen, C.C. Mesenchymal stem cells in the wharton's jelly of the human umbilical cord. *Stem Cells* **2004**, *22*, 1330–1337.

39. Weiss, M.L.; Medicetty, S.; Bledsoe, A.R.; Rachakatla, R.S.; Choi, M.; Merchav, S.; Luo, Y.; Rao, M.S.; Velagaleti, G.; Troyer, D. Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of parkinson's disease. *Stem Cells* **2006**, *24*, 781–792.

40. Baksh, D.; Yao, R.; Tuan, R.S. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. *Stem Cells* **2007**, *25*, 1384–1392.

41. Sarugaser, R.; Lickorish, D.; Baksh, D.; Hosseini, M.M.; Davies, J.E. Human umbilical cord perivascular (hucpv) cells: A source of mesenchymal progenitors. *Stem Cells* **2005**, *23*, 220–229.

42. Bieback, K.; Kluter, H. Mesenchymal stromal cells from umbilical cord blood. *Curr. Stem. Cell Res. Ther.* **2007**, *2*, 310–323.

43. Gang, E.J.; Jeong, J.A.; Han, S.; Yan, Q.; Jeon, C.J.; Kim, H. In vitro endothelial potential of human uc blood-derived mesenchymal stem cells. *Cytotherapy* **2006**, *8*, 215–227.

44. Gang, E.J.; Jeong, J.A.; Hong, S.H.; Hwang, S.H.; Kim, S.W.; Yang, I.H.; Ahn, C.; Han, H.; Kim, H. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. *Stem Cells* **2004**, *22*, 617–624.

45. Hou, L.; Cao, H.; Wang, D.; Wei, G.; Bai, C.; Zhang, Y.; Pei, X., Induction of umbilical cord blood mesenchymal stem cells into neuron-like cells in vitro. *Int. J. Hematol.* **2003**, *78*, 256–261.

46. Lee, O.K.; Kuo, T.K.; Chen, W.M.; Lee, K.D.; Hsieh, S.L.; Chen, T.H. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood* **2004**, *103*, 1669–1675.

47. Bilic, G.; Ochsenbein-Kolble, N.; Hall, H.; Huch, R.; Zimmermann, R. In vitro lesion repair by human amnion epithelial and mesenchymal cells. *Am. J. Obstet. Gynecol.* **2004**, *190*, 87–92.
48. Casey, M.L.; MacDonald, P.C. Keratinocyte growth factor expression in the mesenchymal cells of human amnion. *J. Clin. Endocrinol. Metab* [1997], 82, 3319–3323.

49. Magatti, M.; De, M.S.; Vertua, E.; Gibelli, L.; Wengler, G.S.; Parolini, O. Human amnion mesenchyme harbors cells with allogeneic t-cell suppression and stimulation capabilities. *Stem Cells* [2008], 26, 182–192.

50. Portmann-Lanz, C.B.; Schoeberlein, A.; Huber, A.; Sager, R.; Malek, A.; Holzgreve, W.; Surbek, D.V. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. *Am. J. Obstet. Gynecol.* [2006], 194, 664–673.

51. Sakuragawa, N.; Kakinuma, K.; Kikuchi, A.; Okano, H.; Uchida, S.; Kamo, I.; Kobayashi, M.; Yokoyama, Y. Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells. *J. Neurosci. Res.* [2004], 78, 208–214.

52. Soncini, M.; Vertua, E.; Gibelli, L.; Zorzi, F.; Denegri, M.; Albertini, A.; Wengler, G.S.; Parolini, O. Isolation and characterization of mesenchymal cells from human fetal membranes. *J. Tissue Eng. Regen. Med.* [2007], 1, 296–305.

53. Tamagawa, T.; Oi, S.; Ishiwata, I.; Ishikawa, H.; Nakamura, Y. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells *in vitro*. *Hum. Cell* [2007], 20, 77–84.

54. Whittle, W.L.; Gibb, W.; Challis, J.R. The characterization of human amnion epithelial and mesenchymal cells: The cellular expression, activity and glucocorticoid regulation of prostaglandin output. *Placenta* [2000], 21, 394–401.

55. Wolbank, S.; Peterbauer, A.; Fahrner, M.; Hennersbichler, S.; van, G.M.; Stadler, G.; Redl, H.; Gabriel, C. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: A comparison with human mesenchymal stem cells from adipose tissue. *Tissue Eng* [2007], 13, 1173–1183.

56. Sudo, K.; Kanno, M.; Miharada, K.; Ogawa, S.; Hiroyama, T.; Saijo, K.; Nakamura, Y. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells *in vitro* are present in most primary fibroblast-like cell populations. *Stem Cells* [2007], 25, 1610–1617.

57. Manochantr, S.; Tantrawatpan, C.; Kheolamai, P.; Pratya, Y.; Supokawej, A.; Issaragrisil, S. Isolation, characterization and neural differentiation potential of amnion derived mesenchymal stem cells. *J. Med. Assoc. Thai.* [2010], 93 (Suppl. 7), S183–S191.

58. Tsuji, H.; Miyoshi, S.; Ikegami, Y.; Hida, N.; Asada, H.; Togashi, I.; Suzuki, J.; Satake, M.; Nakamizo, H.; Tanaka, M.; *et al.* Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. *Circ. Res.* [2010], 106, 1613–1623.

59. Miki, T.; Mitamura, K.; Ross, M.A.; Stolz, D.B.; Strom, S.C. Identification of stem cell marker-positive cells by immunofluorescence in term human amnion. *J. Reprod. Immunol.* [2007], 75, 91–96.

60. Bilic, G.; Hall, H.; Bittermann, A.G.; Zammeretti, P.; Burkhart, T.; Oechsenbein-Kolble, N.; Zimmermann, R. Human preterm amnion cells cultured in 3-dimensional collagen i and fibrin matrices for tissue engineering purposes. *Am. J. Obstet. Gynecol.* [2005], 193, 1724–1732.
61. Pasquinelli, G.; Tazzari, P.; Ricci, F.; Vaselli, C.; Buzzi, M.; Conte, R.; Orrico, C.; Foroni, L.; Stella, A.; Alviano, F.; et al. Ultrastructural characteristics of human mesenchymal stromal (stem) cells derived from bone marrow and term placenta. *Ultrastruct. Pathol.* 2007, 31, 23–31.

62. Kadam, S.S.; Bhonde, R.R. Islet neogenesis from the constitutively nestin expressing human umbilical cord matrix derived mesenchymal stem cells. *Islets* 2010, 2, 112–120.

63. Ishige, I.; Nagamura-Inoue, T.; Honda, M.; Harnprasopwat, R.; Kido, M.; Sugimoto, M.; Nakauchi, H.; Tojo, A. Comparison of mesenchymal stem cells derived from arterial, venous, and wharton’s jelly explants of human umbilical cord. *Int. J. Hematol.* 2009, 90, 261.

64. La Rocca, G.; Anzalone, R.; Corrao, S.; Magno, F.; Loria, T.; Lo Iacono, M.; Di Stefano, A.; Giannuzzi, P.; Marasa, L.; Cappello, F.; et al. Isolation and characterization of oct-4+/hla-g+ mesenchymal stem cells from human umbilical cord matrix: Differentiation potential and detection of new markers. *Histochem. Cell. Biol.* 2009, 131, 267–282.

65. Lu, L.L.; Liu, Y.J.; Yang, S.G.; Zhao, Q.J.; Wang, X.; Gong, W.; Han, Z.B.; Xu, Z.S.; Lu, Y.X.; Liu, D.; et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. *Haematologica* 2006, 91, 1017–1026.

66. Schneider, R.K.; Pullen, A.; Kramann, R.; Bornemann, J.; Knuchel, R.; Neuss, S.; Perez-Bouza, A. Long-term survival and characterisation of human umbilical cord-derived mesenchymal stem cells on dermal equivalents. *Differentiation* 2010, 79, 182–193.

67. Tsagias, N.; Koliakos, I.; Karagiannis, V.; Eleftheriadou, M.; Koliakos, G.G. Isolation of mesenchymal stem cells using the total length of umbilical cord for transplantation purposes. *Transfus. Med.* 2011, 21, 253–261.

68. Gonzalez, R.; Griparic, L.; Umana, M.; Burgee, K.; Vargas, V.; Nasrallah, R.; Silva, F.; Patel, A. An efficient approach to isolation and characterization of pre- and postnatal umbilical cord lining stem cells for clinical applications. *Cell Transplant.* 2010, 19, 1439–1449.

69. Kadner, A.; Zund, G.; Maurus, C.; Breymann, C.; Yakarisik, S.; Kadner, G.; Turina, M.; Hoerstrup, S.P. Human umbilical cord cells for cardiovascular tissue engineering: A comparative study. *Eur. J. Cardiothorac. Surg.* 2004, 25, 635–641.

70. Majore, I.; Moretti, P.; Stahl, F.; Hass, R.; Kasper, C. Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. *Stem. Cell. Rev.* 2010, 7, 17–31.

71. Petsa, A.; Gargani, S.; Felesakis, A.; Grigoriadis, N.; Grigoriadis, I. Effectiveness of protocol for the isolation of wharton's jelly stem cells in large-scale applications. *In vitro Cell. Dev. Biol. Anim.* 2009, 45, 573–576.

72. Moretti, P.; Hatlapatka, T.; Marten, D.; Lavrentieva, A.; Majore, I.; Hass, R.; Kasper, C. Mesenchymal stromal cells derived from human umbilical cord tissues: Primitive cells with potential for clinical and tissue engineering applications. *Adv. Biochem. Eng. Biotechnol.* 2010, 123, 29–54.

73. Majore, I.; Moretti, P.; Hass, R.; Kasper, C. Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord. *Cell. Commun. Signal.* 2009, 7, 6.

74. Sivasubramaniyan, K.; Lehnen, D.; Ghazanfari, R.; Sobiesiak, M.; Harichandan, A.; Mortha, E.; Petkova, N.; Grimm, S.; Cerabona, F.; de Zwart, P.; et al. Phenotypic and functional
heterogeneity of human bone marrow- and amnion-derived msc subsets. *Ann. NY Acad. Sci.* 2012, 1266, 94–106.

75. Battula, V.L.; Treml, S.; Bareiss, P.M.; Gieseke, F.; Roelofs, H.; de Zwart, P.; Muller, I.; Schewe, B.; Skutella, T.; Fibbe, W.E.; *et al.* Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against cd56, cd271, and mesenchymal stem cell antigen-1. *Haematologica* 2009, 94, 173–184.

76. Buhring, H.J.; Battula, V.L.; Treml, S.; Schewe, B.; Kanz, L.; Vogel, W. Novel markers for the prospective isolation of human msc. *Ann. NY Acad. Sci.* 2007, 1106, 262–271.

77. Gang, E.J.; Bosnakovski, D.; Figueiredo, C.A.; Visser, J.W.; Perlingeiro, R.C. Ssea-4 identifies mesenchymal stem cells from bone marrow. *Blood* 2007, 109, 1743–1751.

78. Kawanabe, N.; Murata, S.; Fukushima, H.; Ishihara, Y.; Yanagita, T.; Yanagita, E.; Ono, M.; Kurosaka, H.; Kamioka, H.; Itoh, T.; *et al.* Stage-specific embryonic antigen-4 identifies human dental pulp stem cells. *Exp. Cell. Res.* 2012, 318, 453–463.

79. Martinez, C.; Hofmann, T.J.; Marino, R.; Dominici, M.; Horwitz, E.M. Human bone marrow mesenchymal stromal cells express the neural ganglioside gd2: A novel surface marker for the identification of mscs. *Blood* 2007, 109, 4245–4248.

80. Xu, J.; Liao, W.; Gu, D.; Liang, L.; Liu, M.; Du, W.; Liu, P.; Zhang, L.; Lu, S.; Dong, C.; *et al.* Neural ganglioside gd2 identifies a subpopulation of mesenchymal stem cells in umbilical cord. *Cell. Physiol. Biochem.* 2009, 23, 415–424.

81. Cheng, H.; Qiu, L.; Ma, J.; Zhang, H.; Cheng, M.; Li, W.; Zhao, X.; Liu, K. Replicative senescence of human bone marrow and umbilical cord derived mesenchymal stem cells and their differentiation to adipocytes and osteoblasts. *Mol. Biol. Rep.* 2011, 38, 5161–5168.

82. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999, 284, 143–147.

83. Kim, S.W.; Zhang, H.Z.; Kim, C.E.; An, H.S.; Kim, J.M.; Kim, M.H. Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia. *Cardiovasc. Res.* 2012, 93, 525–534.

84. Wei, J.P.; Zhang, T.S.; Kawas, S.; Aizawa, T.; Ota, M.; Akaite, T.; Kato, K.; Konishi, I.; Nikaido, T. Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. *Cell Transplant.* 2003, 12, 545–552.

85. Tamagawa, T.; Ishiwata, I.; Ishikawa, H.; Nakamura, Y. Induced in-vitro differentiation of neural-like cells from human amnion-derived fibroblast-like cells. *Hum. Cell* 2008, 21, 38–45.

86. Chen, M.Y.; Lie, P.C.; Li, Z.L.; Wei, X. Endothelial differentiation of wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. *Exp. Hematol.* 2009, 37, 629–640.

87. Ciavarella, S.; Dammacco, F.; De Matteo, M.; Loverro, G.; Silvestris, F. Umbilical cord mesenchymal stem cells: Role of regulatory genes in their differentiation to osteoblasts. *Stem Cells Dev.* 2009, 18, 1211–1220.

88. Covas, D.T.; Panepucci, R.A.; Fontes, A.M.; Silva, W.A., Jr.; Orellana, M.D.; Freitas, M.C.; Neder, L.; Santos, A.R.; Peres, L.C.; Jamur, M.C.; *et al.* Multipotent mesenchymal stromal cells
obtained from diverse human tissues share functional properties and gene-expression profile with cd146+ perivascular cells and fibroblasts. *Exp. Hematol.* **2008**, *36*, 642–654.

89. Diao, Y.; Ma, Q.; Cui, F.; Zhong, Y. Human umbilical cord mesenchymal stem cells: Osteogenesis *in vivo* as seed cells for bone tissue engineering. *J. Biomed. Mater. Res. A* **2008**, *91*, 123–131.

90. Jo, C.H.; Kim, O.S.; Park, E.Y.; Kim, B.J.; Lee, J.H.; Kang, S.B.; Lee, J.H.; Han, H.S.; Rhee, S.H.; Yoon, K.S. Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. *Cell Tissue Res.* **2008**, *334*, 423–433.

91. Kadam, S.S.; Tiwari, S.; Bhonde, R.R. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. *In Vitro Cell Dev. Biol. Anim.* **2009**, *45*, 23–27.

92. Kadivar, M.; Khatami, S.; Mortazavi, Y.; Shokrgozar, M.A.; Taghikhani, M.; Soleimani, M. *In vitro* cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. *Biochem. Biophys. Res. Commun.* **2006**, *340*, 639–647.

93. Kestendjieva, S.; Kyurkchiev, D.; Tsvetkova, G.; Mehandjiev, T.; Dimitrov, A.; Nikolov, A.; Kyurkchiev, S. Characterization of mesenchymal stem cells isolated from the human umbilical cord. *Cell. Biol. Int.* **2008**, *32*, 724–732.

94. Liu, X.D.; Liu, B.; Li, X.S.; Mao, N. Isolation and identification of mesenchymal stem cells from perfusion of human umbilical cord vein. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* **2007**, *15*, 1019–1022.

95. Lu, L.L.; Song, Y.P.; Wei, X.D.; Fang, B.J.; Zhang, Y.L.; Li, Y.F. Comparative characterization of mesenchymal stem cells from human umbilical cord tissue and bone marrow. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* **2008**, *16*, 140–146.

96. Martin-Rendon, E.; Sweetney, D.; Lu, F.; Girdlestone, J.; Navarrete, C.; Watt, S.M. 5-azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes *in vitro* at high frequencies. *Vox Sang* **2008**, *95*, 137–148.

97. Qiao, C.; Xu, W.; Zhu, W.; Hu, J.; Qian, H.; Yin, Q.; Jiang, R.; Yan, Y.; Mao, F.; Yang, H.; *et al.* Human mesenchymal stem cells isolated from the umbilical cord. *Cell. Biol. Int.* **2008**, *32*, 8–15.

98. Sudo, K.; Kanno, M.; Miharada, K.; Ogawa, S.; Hiroyama, T.; Sajo, K.; Nakamura, Y. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells *in vitro* are present in most primary fibroblast-like cell populations. *Stem Cells* **2007**, *25*, 1610–1617.

99. Suzdal'tseva, Y.G.; Burunova, V.V.; Vakhrushev, I.V.; Yarygin, V.N.; Yarygin, K.N. Capability of human mesenchymal cells isolated from different sources to differentiation into tissues of mesodermal origin. *Bull. Exp. Biol. Med.* **2007**, *143*, 114–121.

100. Tian, X.; Fu, R.Y.; Chen, Y.; Yuan, L.X. Isolation of multipotent mesenchymal stem cells from the tissue of umbilical cord for osteoblasts and adipocytes differentiation. *Sichuan Da Xue Xue Bao Yi Xue Ban* **2008**, *39*, 26–29.

101. Wu, K.H.; Zhou, B.; Lu, S.H.; Feng, B.; Yang, S.G.; Du, W.T.; Gu, D.S.; Han, Z.C.; Liu, Y.L. *In vitro* and *in vivo* differentiation of human umbilical cord derived stem cells into endothelial cells. *J. Cell. Biochem.* **2007**, *100*, 608–616.
102. Zhang, Z.Y.; Teoh, S.H.; Chong, M.S.; Schantz, J.T.; Fisk, N.M.; Choolani, M.A.; Chan, J. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. *Stem Cells* 2009, 27, 126–137.

103. Farias, V.A.; Linares-Fernandez, J.L.; Penalver, J.L.; Paya Colmenero, J.A.; Ferron, G.O.; Duran, E.L.; Fernandez, R.M.; Olivares, E.G.; O'Valle, F.; Puertas, A.; et al. Human umbilical cord stromal stem cell express cd10 and exert contractile properties. *Placenta* 2010, 32, 86–95.

104. Montanucci, P.; Basta, G.; Pescara, T.; Pennoni, I.; Di Giovanni, F.; Calafiore, R. New simple and rapid method for purification of mesenchymal stem cells from the human umbilical cord wharton jelly. *Tissue Eng. Part A* 2011, 17, 2651–2661.

105. Salehinejad, P.; Alitheen, N.B.; Nematollahi-Mahani, S.N.; Ali, A.M.; Omar, A.R.; Janzamin, E.; Hajghani, M. Effect of culture media on expansion properties of human umbilical cord matrix-derived mesenchymal cells. *Cytotherapy* 2012, 14, 948–953.

106. Struys, T.; Moreels, M.; Martens, W.; Donders, R.; Wolfs, E.; Lambriichts, I. Ultrastructural and immunocytochemical analysis of multilineage differentiated human dental pulp- and umbilical cord-derived mesenchymal stem cells. *Cells Tissues Organs* 2011, 193, 366–378.

107. Xu, Z.F.; Pan, A.Z.; Yong, F.; Shen, C.Y.; Chen, Y.W.; Wu, R.H. Human umbilical mesenchymal stem cell and its adipogenic differentiation: Profiling by nuclear magnetic resonance spectroscopy. *World J. Stem. Cells* 2012, 4, 21–27.

108. Qiao, S.M.; Chen, G.H.; Wang, Y.; Wu, D.P. ultrastructure of human umbilical cord mesenchymal stem cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012, 20, 443–447.

109. Zhang, Y.N.; Lie, P.C.; Wei, X. Differentiation of mesenchymal stromal cells derived from umbilical cord wharton's jelly into hepatocyte-like cells. *Cytotherapy* 2009, 11, 548–558.

110. Honsawek, S.; Dhitiseith, D.; Phupong, V. Effects of demineralized bone matrix on proliferation and osteogenic differentiation of mesenchymal stem cells from human umbilical cord. *J. Med. Assoc. Thai* 2006, 89 (Suppl. 3), S189–S195.

111. Hou, T.; Xu, J.; Wu, X.; Xie, Z.; Luo, F.; Zhang, Z.; Zeng, L. Umbilical cord wharton's jelly: A new potential cell source of mesenchymal stromal cells for bone tissue engineering. *Tissue Eng Part A* 2009, 15, 2325–2334.

112. Passeri, S.; Nocchi, F.; Lamanna, R.; Lapi, S.; Miragliotta, V.; Giannessi, E.; Abramo, F.; Sornelli, M.R.; Matarazzo, M.; Plenteda, D.; et al. Isolation and expansion of equine umbilical cord-derived matrix cells (euemcs). *Cell. Biol. Int.* 2009, 33, 100–105.

113. Baba, K.; Yamazaki, Y.; Ikemoto, S.; Aoyagi, K.; Takeda, A.; Uchinuma, E. Osteogenic potential of human umbilical cord-derived mesenchymal stromal cells cultured with umbilical cord blood-derived autoserum. *J. Craniomaxillofac. Surg.* 2012, in press.

114. Kang, M.N.; Yoon, H.H.; Seo, Y.K.; Park, J.K. Effect of mechanical stimulation on the differentiation of cord stem cells. *Connect. Tissue Res.* 2012, 53, 149–159.

115. Xu, Y.; Meng, H.; Li, C.; Hao, M.; Wang, Y.; Yu, Z.; Li, Q.; Han, J.; Zhai, Q.; Qiu, L. Umbilical cord-derived mesenchymal stem cells isolated by a novel explantation technique can differentiate into functional endothelial cells and promote revascularization. *Stem Cells Dev.* 2010, 19, 1511–1522.
116. Pereira, W.C.; Khushnooma, I.; Madkaikar, M.; Ghosh, K. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. *J. Tissue Eng. Regen. Med.* **2008**, *2*, 394–399.

117. Qian, Q.; Qian, H.; Zhang, X.; Zhu, W.; Yan, Y.; Ye, S.; Peng, X.; Li, W.; Xu, Z.; Sun, L.; et al. 5-azacytidine induces cardiac differentiation of human umbilical cord-derived mesenchymal stem cells by activating extracellular regulated kinase. *Stem Cells Dev.* **2012**, *21*, 67–75.

118. Zhao, Z.; Chen, Z.; Zhao, X.; Pan, F.; Cai, M.; Wang, T.; Zhang, H.; Lu, J.R.; Lei, M. Sphingosine-1-phosphate promotes the differentiation of human umbilical cord mesenchymal stem cells into cardiomyocytes under the designated culturing conditions. *J. Biomed. Sci.* **2011**, *18*, 37.

119. Campard, D.; Lysy, P.A.; Najimi, M.; Sokal, E.M. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. *Gastroenterology* **2008**, *134*, 833–848.

120. Zhao, Q.; Ren, H.; Li, X.; Chen, Z.; Zhang, X.; Gong, W.; Liu, Y.; Pang, T.; Han, Z.C. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. *Cytotherapy* **2009**, *11*, 414–426.

121. Wang, H.W.; Lin, L.M.; He, H.Y.; You, F.; Li, W.Z.; Huang, T.H.; Ma, G.X.; Ma, L. Human umbilical cord mesenchymal stem cells derived from wharton's jelly differentiate into insulin-producing cells *in vitro*. *Chin. Med. J. (Engl)* **2011**, *124*, 1534–1539.

122. Wang, H.S.; Shyu, J.F.; Shen, W.S.; Hsu, H.C.; Chi, T.C.; Chen, C.P.; Huang, S.W.; Shyr, Y.M.; Tang, K.T.; Chen, T.H. Transplantation of insulin-producing cells derived from umbilical cord stromal mesenchymal stem cells to treat nod mice. *Cell Transplant.* **2011**, *20*, 455–466.

123. Chao, K.C.; Chao, K.F.; Fu, Y.S.; Liu, S.H. Islet-like clusters derived from mesenchymal stem cells in wharton's jelly of the human umbilical cord for transplantation to control type 1 diabetes. *PLoS ONE* **2008**, *3*, e1451.

124. Wu, L.F.; Wang, N.N.; Liu, Y.S.; Wei, X. Differentiation of wharton's jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells. *Tissue Eng Part A* **2009**, *15*, 2865–2873.

125. Chou, S.C.; Ko, T.L.; Fu, Y.Y.; Wang, H.W.; Fu, Y.S. Identification of genetic networks during mesenchymal stem cell transformation into neurons. *Chin. J. Physiol.* **2008**, *51*, 230–246.

126. Ma, L.; Cui, B.L.; Feng, X.Y.; Law, F.D.; Jiang, X.W.; Yang, L.Y.; Xie, Q.D.; Huang, T.H. Biological characteristics of human umbilical cord-derived mesenchymal stem cells and their differentiation into neurocyte-like cells. *Zhonghua Er Ke Za Zhi* **2006**, *44*, 513–517.

127. Matsuse, D.; Kitada, M.; Kohama, M.; Nishikawa, K.; Makinoshiba, H.; Wakao, S.; Fujiyoshi, Y.; Heike, T.; Nakahata, T.; Akutsu, H.; et al. Human umbilical cord-derived mesenchymal stromal cells differentiate into functional schwann cells that sustain peripheral nerve regeneration. *J. Neuropathol. Exp. Neurol.* **2010**, *69*, 973–985.

128. Cho, H.; Seo, Y.K.; Jeon, S.; Yoon, H.H.; Choi, Y.K.; Park, J.K. Neural differentiation of umbilical cord mesenchymal stem cells by sub-sonic vibration. *Life Sci.* **2012**, *90*, 591–599.

129. Chen, K.; Wang, D.; Du, W.T.; Han, Z.B.; Ren, H.; Chi, Y.; Yang, S.G.; Zhu, D.; Bayard, F.; Han, Z.C. Human umbilical cord mesenchymal stem cells huc-mscs exert immunosuppressive activities through a pge2-dependent mechanism. *Clin. Immunol.* **2010**, *135*, 448–458.
130. Weiss, M.L.; Anderson, C.; Medicetty, S.; Seshareddy, K.B.; Weiss, R.J.; VanderWerff, I.; Troyer, D.; McIntosh, K.R. Immune properties of human umbilical cord wharton's jelly-derived cells. *Stem Cells* 2008, 26, 2865–2874.

131. Zhou, C.; Yang, B.; Tian, Y.; Jiao, H.; Zheng, W.; Wang, J.; Guan, F. Immunomodulatory effect of human umbilical cord wharton's jelly-derived mesenchymal stem cells on lymphocytes. *Cell Immunol.* 2011, 272, 33–38.

132. Bailo, M.; Soncini, M.; Vertua, E.; Signoroni, P.B.; Sanzone, S.; Lombardi, G.; Arienti, D.; Calamani, F.; Zatti, D.; Paul, P.; et al. Engraftment potential of human amnion and chorion cells derived from term placenta. *Transplantation* 2004, 78, 1439–1448.

133. Weiss, M.L.; Mitchell, K.E.; Hix, J.E.; Medicetty, S.; El-Zarkouny, S.Z.; Grieger, D.; Troyer, D.L. Transplantation of porcine umbilical cord matrix cells into the rat brain. *Exp. Neurol.* 2003, 182, 288–299.

134. Liao, W.; Xie, J.; Zhong, J.; Liu, Y.; Du, L.; Zhou, B.; Xu, J.; Liu, P.; Yang, S.; Wang, J.; et al. Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. *Transplantation* 2009, 87, 350–359.

135. Medicetty, S.; Bledsoe, A.R.; Fahrenholtz, C.B.; Troyer, D.; Weiss, M.L. Transplantation of pig stem cells into rat brain: Proliferation during the first 8 weeks. *Exp. Neurol.* 2004, 190, 32–41.

136. Ennis, J.; Gotherstrom, C.; Le Blanc, K.; Davies, J.E. *In vitro* immunologic properties of human umbilical cord perivascular cells. *Cytotherapy* 2008, 10, 174–181.

137. Hatlapatka, T.; Moretti, P.; Lavrentieva, A.; Hass, R.; Marquardt, N.; Jacobs, R.; Kasper, C. Optimization of culture conditions for the expansion of umbilical cord-derived mesenchymal stem or stromal cell-like cells using xeno-free culture conditions. *Tissue Eng. Part C Methods* 2011, 17, 485–493.

138. Girdlestone, J.; Limbani, V.A.; Cutler, A.J.; Navarrete, C.V. Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions. *Cytotherapy* 2009, 11, 738–748.

139. Yoo, K.H.; Jang, I.K.; Lee, M.W.; Kim, H.E.; Yang, M.S.; Eom, Y.; Lee, J.E.; Kim, Y.J.; Yang, S.K.; Jung, H.L.; et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. *Cell Immunol.* 2009, 259, 150–156.

140. Ramasamy, R.; Tong, C.K.; Yip, W.K.; Vellasamy, S.; Tan, B.C.; Seow, H.F. Basic fibroblast growth factor modulates cell cycle of human umbilical cord-derived mesenchymal stem cells. *Cell Prolif.* 2012, 45, 132–139.

141. Cutler, A.J.; Limbani, V.; Girdlestone, J.; Navarrete, C.V. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress t cell proliferation. *J. Immunol.* 2010, 185, 6617–6623.

142. Che, N.; Li, X.; Zhou, S.; Liu, R.; Shi, D.; Lu, L.; Sun, L. Umbilical cord mesenchymal stem cells suppress b-cell proliferation and differentiation. *Cell Immunol.* 2012, 274, 46–53.

143. Kronsteiner, B.; Peterbauer-Scherb, A.; Grillari-Voglauer, R.; Redl, H.; Gabriel, C.; van, G.M.; Wolbank, S. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. *Cell Immunol.* 2011, 267, 30–38.
144. Jiang, X.X.; Zhang, Y.; Liu, B.; Zhang, S.X.; Wu, Y.; Yu, X.D.; Mao, N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105, 4120–4126.

145. Nauta, A.J.; Kruisselbrink, A.B.; Lurvink, E.; Willemze, R.; Fibbe, W.E. Mesenchymal stem cells inhibit generation and function of both cd34+-derived and monocyte-derived dendritic cells. J. Immunol. 2006, 177, 2080–2087.

146. Ramasamy, R.; Fazekasova, H.; Lam, E.W.; Soeiro, I.; Lombardi, G.; Dazzi, F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007, 83, 71–76.

147. van den Berk, L.C.; Roelofs, H.; Huijs, T.; Siebers-Vermeulen, K.G.; Raymakers, R.A.; Kogler, G.; Figdor, C.G.; Torensma, R. Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin-12 production by mature dendritic cells. Immunology 2009, 128, 564–572.

148. Kermani, A.J.; Fathi, F.; Mowla, S.J. Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: Potential application in cell-based gene therapy. Rejuvenation Res. 2008, 11, 379–386.

149. Liang, X.J.; Chen, X.J.; Yang, D.H.; Huang, S.M.; Sun, G.D.; Chen, Y.P. Differentiation of human umbilical cord mesenchymal stem cells into hepatocyte-like cells by htert gene transfection in vitro. Cell. Biol. Int. 2012, 36, 215–221.

150. The U.S. National Institutes of Health and the National Library of Medicine, Clinicaltrials.Gov: A database of clinical studies of human participants. Website online: http://clinicaltrials.gov/ct2/home (accessed on 22 August 2012),

151. The U.S. National Institutes of Health and the National Library of Medicine, Clinicaltrials.Gov identifier: Nct01291329. Available on line: http://clinicaltrials.gov/ct2/home (accessed on 22 August 2012),

152. Breymann, C.; Schmidt, D.; Hoerstrup, S.P. Umbilical cord cells as a source of cardiovascular tissue engineering. Stem. Cell. Rev. 2006, 2, 87–92.

153. Hua, J.; Qiu, P.; Zhu, H.; Cao, H.; Wang, F.; Li, W. Multipotent mesenchymal stem cells (mscs) from human umbilical cord: Potential differentiation of germ cells. Afr. J. Biochem. Res. 2011, 5, 113–123.

154. Hilfiker, A.; Kasper, C.; Hass, R.; Haverich, A. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: Is there a future for transplantation? Langenbecks Arch. Surg. 2011, 396, 489–497.